Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New approaches to treatment of primary immunodeficiencies: fixing mutations with chemicals.

Current opinion in allergy and clinical immunology - 1 Dec 2008

Hu Hailiang, Gatti Richard A

Abstract excerpt

PURPOSE OF REVIEW: This review is to highlight the most current mutation-targeted therapeutic approaches and provide insights into new developments for treating primary immunodeficiencies. RECENT FINDINGS: Significant progress in mutation-targeted treatment was achieved in the past year with the identification and characterization of a translational read-through compound, PTC124. PTC124 demonstrates a new class...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood-Brain Barrier
Share to Immunologic Deficiency Syndromes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukocytes

Share to Mutation

Share to Neurons

Share to Oligonucleotides, Antisense

Share to Oxadiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 18978469
DOI: 10.1097/ACI.0b013e328314b63b
PMCID: PMC2686128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New approaches to treatment of primary immunodeficiencies: fixing mutations with chemicals.PMID 18978469Read ↗

New approaches to the treatment of orphan genetic disorders: Mitigating molecular pathologies using chemicals.Semantic proximity Read ↗

Emerging genetic therapies to treat Duchenne muscular dystrophy.Semantic proximity Read ↗

Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development TherapeuticsSemantic proximity Read ↗

Therapeutic antisense oligonucleotides for movement disordersSemantic proximity Read ↗

Splicing modulation therapy in the treatment of genetic diseasesSemantic proximity Read ↗

Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular DystrophySemantic proximity Read ↗

Molecular treatments in Duchenne muscular dystrophy.Semantic proximity Read ↗

Potential therapeutic applications of antisense morpholino oligonucleotides in modulation of splicing in primary immunodeficiency diseases.Semantic proximity Read ↗

Gene therapy for primary immunodeficiencySemantic proximity Read ↗

Splice-switching antisense oligonucleotides as therapeutic drugsSemantic proximity Read ↗

Therapeutic Potential of Tricyclo-DNA antisense oligonucleotidesSemantic proximity Read ↗

A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.